Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens

Phase 1 Trial of SL-172154 in Treating Advanced Ovarian Cancer Opens
Shattuck Labs has opened a Phase 1 clinical trial to investigate its lead candidate, SL-172154, in treating people with advanced ovarian cancer, the company announced in a press release. The trial (NCT04406623) is recruiting up to 33 patients at three sites in the U.S.: the John Wayne Cancer Institute at Providence St. John's Health Center in California, START Midwest in Michigan, and the Stephenson Cancer Center at Oklahoma University. For more information, click here. SL-172154 is designed to modulate a patient's immune system to destroy cancer cells, unlike many treatments that directly target cancer cells. Developed with Shattuck's agonist redirected checkpoint (ARC) platform, the candidate is essentially a fusion protein that binds to two distinct proteins in cells. One is the CD47 molecule on cancer cells that interacts with the SIRPα protein at the surface of
Subscribe or to access all post and page content.